Literature DB >> 16793187

Dysregulation of tau phosphorylation is a hypothesized point of convergence in the pathogenesis of alzheimer's disease, frontotemporal dementia and schizophrenia with therapeutic implications.

Stephen I Deutsch1, Richard B Rosse, Raj M Lakshman.   

Abstract

Two members of the family of low-density lipoprotein receptors (i.e., very low-density lipoprotein [VLDL] receptor and apolipoprotein E [apoE] type 2 receptor) are expressed in brain, where they bind and transduce reelin, a secreted glycoprotein that shares structural analogies with extracellular matrix proteins. In the developing fetal brain, reelin-signal transduction is critical for the correct positioning of neurons and the formation of appropriate synaptic connections, whereas in the mature brain, reelin participates in the mediation of experience-dependent synaptic plasticity. An important "downstream" consequence of the reelin-signal transduction cascade is inhibition of the phosphorylation of tau, a protein that regulates microtubule assembly and stability. Importantly, hyperphosphorylated tau comprises the paired helical filament, whose pathological deposition as neurofibrillary tangles is implicated in Alzheimer's disease; hyperphosphorylated tau is also implicated in the pathogenesis of other neurodegenerative disorders. Isoforms of apoE may affect the binding of reelin to its cell surface receptors and, thereby, influence tau phosphorylation, whereas insulin, insulin-like growth factor-1, and the lithium ion have actions within the cell at the level of the specific tyrosine kinases involved in the phosphorylation of tau. These data support the exploration of pharmacotherapeutic interventions designed to prevent or reduce the burden of hyperphosphorylated tau. Impaired reelin-signal transduction due to an actual deficiency of reelin expression may occur in at least some patients with psychotic disorders, especially schizophrenia; conceivably, hyperphosphorylation of tau would result from deficient transduction of reelin in schizophrenia. Schizophrenia has been conceptualized as a neurodevelopmental disorder of impaired synaptic "connectivity", whose consequence does not become fully apparent until late adolescence or early adulthood. In summary, hyperphosphorylation of tau may be an underlying point of pathological convergence for several neuropsychiatric disorders, and prevention of tau hyperphosphorylation may be an important therapeutic target.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16793187     DOI: 10.1016/j.pnpbp.2006.04.007

Source DB:  PubMed          Journal:  Prog Neuropsychopharmacol Biol Psychiatry        ISSN: 0278-5846            Impact factor:   5.067


  13 in total

1.  Development of frontotemporal dementia in a case of bipolar affective disorder: is there a link?

Authors:  Aleksandar Pavlovic; Justin Marley; Velusamy Sivakumar
Journal:  BMJ Case Rep       Date:  2011-02-02

2.  Exploration of CAG triplet repeat in nontranslated region of SCA12 gene.

Authors:  Waseem Gul Lone; Imran Ali Khan; Subhadra Poornima; Noor Ahmad Shaik; Angmuthu Kanikannan Meena; Kaipa Prabhakar Rao; Qurratulain Hasan
Journal:  J Genet       Date:  2016-06       Impact factor: 1.166

3.  Serotonin transporter and saitohin genes in risk of Alzheimer's disease and frontotemporal lobar dementia: preliminary findings.

Authors:  Cristina Lorenzi; Alessandra Marcone; Adele Pirovano; Elena Marino; Francesco Cordici; Chiara Cerami; Dario Delmonte; Stefano F Cappa; Placido Bramanti; Enrico Smeraldi
Journal:  Neurol Sci       Date:  2010-09-18       Impact factor: 3.307

4.  Microtube Array Membrane Encapsulated Cell Therapy: A Novel Platform Technology Solution for Treatment of Alzheimer's Disease.

Authors:  Shu-Mei Chen; Tsung-Chin Hsu; Chee-Ho Chew; Wan-Ting Huang; Amanda Lin Chen; Yung-Feng Lin; Sabiha Eddarkaoui; Luc Buee; Chien-Chung Chen
Journal:  Int J Mol Sci       Date:  2022-06-20       Impact factor: 6.208

Review 5.  Β-Amyloid Burden is Not Associated with Cognitive Impairment in Schizophrenia: A Systematic Review.

Authors:  Jun Ku Chung; Shinichiro Nakajima; Eric Plitman; Yusuke Iwata; Danielle Uy; Philip Gerretsen; Fernando Caravaggio; M Mallar Chakravarty; Ariel Graff-Guerrero
Journal:  Am J Geriatr Psychiatry       Date:  2016-04-29       Impact factor: 4.105

Review 6.  Neurodegenerative aspects in vulnerability to schizophrenia spectrum disorders.

Authors:  Trevor Archer; Serafino Ricci; Danilo Garcia; Max Rapp Ricciardi
Journal:  Neurotox Res       Date:  2014-05-08       Impact factor: 3.911

7.  Uncovering molecular biomarkers that correlate cognitive decline with the changes of hippocampus' gene expression profiles in Alzheimer's disease.

Authors:  Martín Gómez Ravetti; Osvaldo A Rosso; Regina Berretta; Pablo Moscato
Journal:  PLoS One       Date:  2010-04-13       Impact factor: 3.240

8.  Reelin is a platelet protein and functions as a positive regulator of platelet spreading on fibrinogen.

Authors:  Wei-Lien Tseng; Chien-Ling Huang; Kowit-Yu Chong; Chang-Huei Liao; Arnold Stern; Ju-Chien Cheng; Ching-Ping Tseng
Journal:  Cell Mol Life Sci       Date:  2009-11-21       Impact factor: 9.261

Review 9.  Effect of aging on cellular mechanotransduction.

Authors:  Miaozong Wu; Jacqueline Fannin; Kevin M Rice; Bin Wang; Eric R Blough
Journal:  Ageing Res Rev       Date:  2009-11-20       Impact factor: 10.895

10.  GSK-3β Disrupts Neuronal Oscillatory Function to Inhibit Learning and Memory in Male Rats.

Authors:  Abdalla M Albeely; Olivia O F Williams; Melissa L Perreault
Journal:  Cell Mol Neurobiol       Date:  2021-01-03       Impact factor: 5.046

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.